Shenzhen Pharmacin Co., Ltd.

This Phase I clinical study is divided into two parts. Phase Ia aims to evaluate the safety, tolerability and pharmacokinetic characteristics of HLK-6002 ointment of different strengths from low to high concentrations in healthy adult volunteers, and Phase Ib aims to evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of HLK-6002 ointment of different strengths in patients with plaque psoriasis.

Primary Objective: To evaluate the safety and tolerability of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis; 2) To preliminarily evaluate the efficacy of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis, and to explore the optimal dose of HLK-5003 in these patients, providing a basis for subsequent clinical trials.